CLINICAL_TRIALS
trial_result
· 2024-12-13
Clinical Trial Update: Ibrutinib and Rituxan for Chronic GVHD [Phase 2]
Summary
Phase 2 trial of combination therapy with ibrutinib and rituximab for chronic graft-versus-host disease has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Northside Hospital, Inc. | Conditions: Graft Vs Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-12-13